Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmaceutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral Janssen-Cilag) in Patients With Tinea Pedis

Trial Profile

Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmaceutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral Janssen-Cilag) in Patients With Tinea Pedis

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Dapaconazole (Primary)
  • Indications Tinea pedis
  • Focus Registrational; Therapeutic Use
  • Sponsors Biolab Sanus Farmaceutica
  • Most Recent Events

    • 31 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 05 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.
    • 05 Feb 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top